Display options
Cite
Tournaire G, Despas F, Huguet F, et al. Peripheral arterial occlusive disease during ponatinib therapy after failure of imatinib: a case report. J Clin Pharm Ther. 2016;41(3):360-361doi: 10.1111/jcpt.12383.
Tournaire, G., Despas, F., Huguet, F., Montastruc, J. L., & Bondon-Guitton, E. (2016). Peripheral arterial occlusive disease during ponatinib therapy after failure of imatinib: a case report. Journal of clinical pharmacy and therapeutics, 41(3), 360-361. https://doi.org/10.1111/jcpt.12383
Tournaire, G, et al. "Peripheral arterial occlusive disease during ponatinib therapy after failure of imatinib: a case report." Journal of clinical pharmacy and therapeutics vol. 41,3 (2016): 360-361. doi: https://doi.org/10.1111/jcpt.12383
Tournaire G, Despas F, Huguet F, Montastruc JL, Bondon-Guitton E. Peripheral arterial occlusive disease during ponatinib therapy after failure of imatinib: a case report. J Clin Pharm Ther. 2016 Jun;41(3):360-361. doi: 10.1111/jcpt.12383. Epub 2016 Mar 23. PMID: 27009771.
Copy Download .nbib Format: NLM
Share it on

J Clin Pharm Ther. 2016 Jun;41(3):360-361. doi: 10.1111/jcpt.12383. Epub 2016 Mar 23.

Peripheral arterial occlusive disease during ponatinib therapy after failure of imatinib: a case report.

Journal of clinical pharmacy and therapeutics

G Tournaire, F Despas, F Huguet, J L Montastruc, E Bondon-Guitton

Affiliations

  1. Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de Pharmacovigilance, Pharmacoépidémiologie et Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, Faculté de Médecine de l'Université de Toulouse, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
  2. Service de Pharmacologie Médicale et Clinique, Faculté de Médecine de l'Université de Toulouse, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
  3. Service d'Hématologie, Institut Universitaire du Cancer, Toulouse, France.

PMID: 27009771 DOI: 10.1111/jcpt.12383

Abstract

WHAT IS KNOWN AND OBJECTIVE: Peripheral vascular adverse events have been reported with ponatinib treatment in chronic myeloid leukaemia (CML) after failure of dasatinib or nilotinib. We here report peripheral arterial occlusive disease (PAOD) in a patient who had previously received only imatinib as tyrosine kinase inhibitor.

CASE DESCRIPTION: The patient was a 70-year-old man with no history of cardiovascular disease. He developed arterial hypertension 5 months after the initiation of ponatinib and PAOD 41 months later.

WHAT IS NEW AND CONCLUSION: Peripheral arterial occlusive disease can occur several years after the initiation of ponatinib in patients who had previously received only imatinib. Long-term surveillance is required for preventing the complications of ponatinib-associated PAOD.

© 2016 John Wiley & Sons Ltd.

Keywords: adverse drug reactions; protein kinase inhibitors; risk factors; vasculopathies

Publication Types